Samsung Biologics, Celltrion pledge major CO2 cuts

Samsung Biologics, Celltrion pledge major CO2 cuts

South Korea’s No. 1 biopharmaceutical company Samsung BioLogics Co. and No. 2 Celltrion Inc. produced higher CO2 emissions last year than in 2...

Celltrion Healthcare launches Humira biosimilar Yuflyma in US

Celltrion Healthcare launches Humira biosimilar Yuflyma in US

South Korean biopharmaceutical company Celltrion Healthcare on Monday said it launched the day before on the US market Yuflyma, a biosimilar of the ...

GC Biopharma inks $90mn deal for blood products in Brazil

GC Biopharma inks $90mn deal for blood products in Brazil

South Korea's GC Biopharma Corp. on Monday announced on Monday that it has a supply contract with Blau Farmacêutica, a Brazilian pharmaceutica...

Celltrion applies for approval in US for eye treatment biosimilar

Celltrion applies for approval in US for eye treatment biosimilar

South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...

Celltrion puts Takeda’s assets up for sale after 3 years

Celltrion puts Takeda’s assets up for sale after 3 years

South Korea’s Celltrion Inc. has put its Japanese Takeda Pharmaceutical Co.'s primary care assets acquired in 2020 on sale as the biosimilar g...

Celltrion wins phase 3 IND approval for Ocrevus biosimilar in US

Celltrion wins phase 3 IND approval for Ocrevus biosimilar in US

South Korea's biopharmaceutical company Celltrion Inc. announced that it received on Thursday approval from the US Food and Drug Administration (FDA...

Celltrion to expand biosimilar portfolio to 11 by 2025

Celltrion to expand biosimilar portfolio to 11 by 2025

South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it plans to beef up its portfolio by applying for regulatory approv...

Celltrion to develop Humira biosimilar oral medication with US firm

Celltrion to develop Humira biosimilar oral medication with US firm

South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...

Celltrion’s Remsima SC praised in Europe as preferred biosimilar

Celltrion’s Remsima SC praised in Europe as preferred biosimilar

MILAN – South Korea's biopharmaceutical company Celltrion Inc. is known in Europe for its biosimilar products such as autoimmune disease treat...

Celltrion unveils phase 1 clinical data of Actemra biosimilar in Europe

Celltrion unveils phase 1 clinical data of Actemra biosimilar in Europe

South Korean biosimilar giant Celltrion Inc. revealed on Wednesday the highly anticipated clinical phase 1 data for its Actemra biosimilar, CT-P47, ...

BIO USA 2023 to draw S.Korean biotech leaders, startups

BIO USA 2023 to draw S.Korean biotech leaders, startups

More than 500 South Korean companies from top business groups to AI-based biotech startups are slated to attend the Bio International Convention 202...

Celltrion gets FDA approval for Humira biosimilar CT-P17

Celltrion gets FDA approval for Humira biosimilar CT-P17

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...

Celltrion Healthcare launches Remsima SC in Brazil

Celltrion Healthcare launches Remsima SC in Brazil

South Korean biopharmaceutical company Celltrion Healthcare Co. revealed on Monday its introduction of Remsima SC, a treatment for autoimmune diseas...

Celltrion drops bid to acquire Baxter’s biopharm unit

Celltrion drops bid to acquire Baxter’s biopharm unit

Celltrion Inc. announced on Tuesday it has decided not to pursue the acquisition of the biopharmaceutical unit of U.S. medical device maker Baxter I...

Celltrion applies for Phase 3 clinical trials in Europe for biosimilar

Celltrion applies for Phase 3 clinical trials in Europe for biosimilar

South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...

Celltrion Healthcare enters top 10 in hospital prescriptions in Turkey

Celltrion Healthcare enters top 10 in hospital prescriptions in Turkey

South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...

MBK Partners co-founder tops 50 richest S.Koreans: Forbes

MBK Partners co-founder tops 50 richest S.Koreans: Forbes

Michael ByungJu Kim, co-founder and partner at private equity firm MBK Partners, has topped the ranking of the 50 richest South Koreans by net worth...

S.Korea's Celltrion Healthcare launches Vegzelma in US

S.Korea's Celltrion Healthcare launches Vegzelma in US

South Korea's Celltrion Healthcare Co. on Monday said it launched on the US market Vegzelma, a biosimilar of Bevacizumab, a medication for colorecta...

Biosimilar giant Celltrion to transform into drug developer

Biosimilar giant Celltrion to transform into drug developer

South Korean biosimilar giant Celltrion Group aims to transform into a drug developer by generating 40% of sales from new medicines by 2030 as it is...

Celltrion founder returns to management with M&A pledge

Celltrion founder returns to management with M&A pledge

South Korean biosimilar giant Celltrion Group’s founder Seo Jung-jin has returned to management two years after his departure, pledging to mer...

Celltrion eyes Baxter's arm as it gears up for M&As

Celltrion eyes Baxter's arm as it gears up for M&As

Celltrion Inc., South Korea’s largest biosimilar maker, said on Tuesday it has studied a possible acquisition of the biopharma solutions unit ...

Celltrion, Genuv sign agreement for antibody joint R&D

Celltrion, Genuv sign agreement for antibody joint R&D

South Korean biopharmaceutical firm Celltrion Inc. announced on Tuesday a joint research and development agreement with Genuv, Inc., a domestic drug...

Celltrion ex-Chairman Seo set to return to management; group stocks rally

Celltrion ex-Chairman Seo set to return to management; group stocks rally

South Korea’s biosimilar giant Celltrion Group’s founder and Honorary Chairman Seo Jung-jin is readying to return to management just two...

Celltrion teams up with bio venture to develop new anti-cancer drug

Celltrion teams up with bio venture to develop new anti-cancer drug

South Korea's biopharmaceutical company Celltrion Inc. will develop an anti-cancer drug that combines oncolytic virus technology with biosimilars un...

Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico

Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico

South Korea’s Daewoong Pharmaceutical Co. said on Feb. 24 it is set to embark on global sales of Envlo, a new drug for diabetes, by exportin...

Brazil approves Celltrion Pharm’s syringe facility

Brazil approves Celltrion Pharm’s syringe facility

Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for it...

S.Korea's Hwajin Medical gets FDA sales approval for syringes

S.Korea's Hwajin Medical gets FDA sales approval for syringes

HLB Therapeutics Co. announced Thursday that Sofjec, a syringe produced by its subsidiary Hwajin Medical, has been approved for sale by the US Food ...

Celltrion's Truxima shows safety, efficacy in post-marketing study

Celltrion's Truxima shows safety, efficacy in post-marketing study

South Korean biopharmaceutical company Celltrion Inc. reported on Wednesday that its biosimilar drug Truxima (rituximab), a generic version of Roche...

Nibec gets approval for its bone graft biomaterials in Colombia, Mexico

Nibec gets approval for its bone graft biomaterials in Colombia, Mexico

South Korea's bioactive peptide technology company Nibec Co. said on Friday that it has obtained product approval for the sale of two types of denta...

Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan

Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan

Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizum...

Deal graveyard: S.Korean F&B franchises left without takers LG Energy, GM’s JV Ultium Cells to retrofit Tennessee plant to produce LFP batteries KPop Demon Hunters OST lands at No.6 on Billboard Hot 100 K-beauty craze sends Olive Young online sales to new heights Hyundai Motor’s high-stakes gambit in US: Cut vehicle prices as rivals hike